We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood Plasma Tests Measure Tumor Load

By HospiMedica staff writers
Posted on 07 Apr 2006
Assays for genetic components of leukemia and lymphoma using blood plasma instead of bone marrow measure "tumor load,” detect blood cancer markers, and assess patient response to therapy.

Leumeta assays, developed by Quest Diagnostics (Lyndhurst, NJ, USA), allow for detection of specific proteins, DNA, RNA, or other molecular targets expressed on or within tumor cells without painful bone marrow extraction. More...
Studies presented at the American Society of Hematology meeting in December 2005 showed that information about tumor load and blood cancer markers of leukemia and lymphoma tumors is contained in blood plasma.

Francis Giles, M.D., professor of medicine and chief of developmental therapies in the department of leukemia at the M.D. Anderson Cancer Center (Houston, Texas, USA), noted, "In an era of increasing focus on targeted therapies, the ability to sequentially obtain so much data from blood plasma specimens is a major help in optimally using the available therapies, and in assessing the efficiency of novel agents. To obtain this data without the need for bone marrow tissue is a major advance.”

The Leumeta assays were developed by a team of researchers at Quest Diagnostics using licensed technology discovered by one of the researchers while previously at M.D. Anderson Cancer Center.



Related Links:
Quest Diagnostics
M.D. Anderson Cancer Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.